ISIN | LU1540961759 |
---|---|
Valor Number | 35003342 |
Bloomberg Global ID | |
Fund Name | HBM UCITS (Lux) Funds-HBM Global Biotechnology Fund A USD Cap |
Fund Provider |
HBM Partners AG
Zug, Schweiz Phone: +41 43 888 71 71 E-Mail: investorrelations@hbmpartners.com Web: www.hbmpartners.com |
Fund Provider | HBM Partners AG |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | FundPartner Solutions (Suisse) S.A. |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 561.01 USD | 09.10.2025 |
---|---|---|
Previous Price * | 554.81 USD | 08.10.2025 |
52 Week High * | 561.01 USD | 09.10.2025 |
52 Week Low * | 384.79 USD | 08.04.2025 |
NAV * | 561.01 USD | 09.10.2025 |
Issue Price * | 561.01 USD | 09.10.2025 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 22,582,511 | |
Unit/Share Assets *** | 4,048,517 | |
Trading Information SIX |
YTD Performance | +23.74% |
31.12.2024 - 09.10.2025
31.12.2024 09.10.2025 |
---|---|---|
YTD Performance (in CHF) | +9.90% |
31.12.2024 - 09.10.2025
31.12.2024 09.10.2025 |
1 month | +7.46% |
09.09.2025 - 09.10.2025
09.09.2025 09.10.2025 |
3 months | +23.78% |
09.07.2025 - 09.10.2025
09.07.2025 09.10.2025 |
6 months | +41.92% |
09.04.2025 - 09.10.2025
09.04.2025 09.10.2025 |
1 year | +17.22% |
09.10.2024 - 09.10.2025
09.10.2024 09.10.2025 |
2 years | +49.32% |
09.10.2023 - 09.10.2025
09.10.2023 09.10.2025 |
3 years | +54.57% |
12.10.2022 - 09.10.2025
12.10.2022 09.10.2025 |
5 years | +20.37% |
14.10.2020 - 09.10.2025
14.10.2020 09.10.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
argenx SE | 6.00% | |
---|---|---|
Alnylam Pharmaceuticals Inc | 5.30% | |
Vertex Pharmaceuticals Inc | 4.83% | |
Ascendis Pharma AS ADR | 4.68% | |
Gilead Sciences Inc | 4.51% | |
Merus NV | 4.28% | |
Xenon Pharmaceuticals Inc | 4.24% | |
Madrigal Pharmaceuticals Inc | 4.10% | |
Arcutis Biotherapeutics Inc Ordinary Shares | 3.80% | |
Amgen Inc | 3.78% | |
Last data update | 30.06.2025 |
TER | 0.0238% |
---|---|
TER date | 31.01.2018 |
Performance Fee *** | 15.00% |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 3.00% |
SRRI ***
|
|
SRRI date *** | 30.09.2025 |